These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37976183)

  • 1. Selenium supplementation in thyroid eye disease: an updated review from a clinical ophthalmic perspective.
    Foos W; Maliakkal Hernandez J; Mansour TN
    Orbit; 2023 Nov; ():1-11. PubMed ID: 37976183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [LIFESTYLE ADJUSTMENT AS THERAPEUTIC TOOL IN THYROID EYE DISEASE].
    Vashdi I; Gur Z
    Harefuah; 2022 Apr; 161(4):223-227. PubMed ID: 35466606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selenium and Thyroid Disease: From Pathophysiology to Treatment.
    Ventura M; Melo M; Carrilho F
    Int J Endocrinol; 2017; 2017():1297658. PubMed ID: 28255299
    [No Abstract]   [Full Text] [Related]  

  • 4. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial.
    Watt T; Cramon P; Bjorner JB; Bonnema SJ; Feldt-Rasmussen U; Gluud C; Gram J; Hansen JL; Hegedüs L; Knudsen N; Bach-Mortensen P; Nolsøe R; Nygaard B; Pociot F; Skoog M; Winkel P; Rasmussen AK
    Trials; 2013 Apr; 14():119. PubMed ID: 23782950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
    Edmunds MR; Boelaert K
    Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is selenium supplementation in autoimmune thyroid diseases justified?
    Winther KH; Bonnema SJ; Hegedüs L
    Curr Opin Endocrinol Diabetes Obes; 2017 Oct; 24(5):348-355. PubMed ID: 28639965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Pathways of Selenium in the Treatment of Graves' Disease and Graves' Orbitopathy.
    Marinò M; Dottore GR; Leo M; Marcocci C
    Horm Metab Res; 2018 Dec; 50(12):887-893. PubMed ID: 30096720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid eye disease or Graves' orbitopathy: What name to use, and why it matters.
    Wagner LH; Bradley EA; Tooley AA; Ren Y; Rachmasari KN; Stan MN
    Front Endocrinol (Lausanne); 2022; 13():1083886. PubMed ID: 36518254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severity of thyroid eye disease and type-2 diabetes mellitus: Is there a correlation?
    Ramamurthy LB; Rangarajan V; Srirao N; Malini B; Bansal R; Yuvarajan K
    Indian J Ophthalmol; 2020 Jun; 68(6):1127-1131. PubMed ID: 32461446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy.
    Negro R; Hegedüs L; Attanasio R; Papini E; Winther KH
    Eur Thyroid J; 2019 Jan; 8(1):7-15. PubMed ID: 30800636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Search for relevant indications for selenium supplementation in thyroid diseases.
    Wojciechowska-Durczynska K; Lewinski A
    Neuro Endocrinol Lett; 2017 Aug; 38(4):237-241. PubMed ID: 28871707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Survey on the Management of Thyroid Eye Disease Among American and European Thyroid Association Members.
    Brito JP; Nagy EV; Singh Ospina N; Zˇarković M; Dosiou C; Fichter N; Lucarelli MJ; Hegedüs L
    Thyroid; 2022 Dec; 32(12):1535-1546. PubMed ID: 35946071
    [No Abstract]   [Full Text] [Related]  

  • 13. Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy.
    Bednarczuk T; Schomburg L
    Hormones (Athens); 2020 Mar; 19(1):31-39. PubMed ID: 31721133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral selenium improved the disease activity in patients with mild Graves' orbitopathy.
    Almanza-Monterrubio M; Garnica-Hayashi L; Dávila-Camargo A; Nava-Castañeda Á
    J Fr Ophtalmol; 2021 May; 44(5):643-651. PubMed ID: 33863564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States.
    Wang Y; Sharma A; Padnick-Silver L; Francis-Sedlak M; Holt RJ; Foley C; Massry G; Douglas RS
    Ophthalmol Ther; 2021 Mar; 10(1):75-87. PubMed ID: 33196932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survey on selenium clinical supplementation in autoimmune thyroid disease.
    Santos LR; Vasconcelos Bessa I; Gaspar da Rocha A; Neves C; Freitas C; Soares P
    Eur Thyroid J; 2023 Apr; 12(2):. PubMed ID: 36622057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.
    Farag S; Feeney C; Lee V; Nagendran S; Jain R; Aziz A; Akishar R; Bravis V; Meeran K
    Front Endocrinol (Lausanne); 2021; 12():669871. PubMed ID: 34025584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of orbital soft tissue biomechanical parameters in patients with thyroid eye disease using the non-contact Corvis ST.
    Moeen Rad A; Zarei-Ghanavati S; Sabermoghaddam A; Ghavami Shahri SH; Bakhtiari E; Kiarudi MY
    Int Ophthalmol; 2023 Oct; 43(10):3615-3621. PubMed ID: 37393605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
    Wall JR; Lahooti H
    Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future Projections in Thyroid Eye Disease.
    Barbesino G; Salvi M; Freitag SK
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.